These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34285339)

  • 21. Genetic and epigenetic aspects of breast cancer progression and therapy.
    Byler S; Goldgar S; Heerboth S; Leary M; Housman G; Moulton K; Sarkar S
    Anticancer Res; 2014 Mar; 34(3):1071-7. PubMed ID: 24596345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the HER2 receptor in metastatic breast cancer.
    Orphanos G; Kountourakis P
    Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
    Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
    Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.
    Zafonte BT; Hulit J; Amanatullah DF; Albanese C; Wang C; Rosen E; Reutens A; Sparano JA; Lisanti MP; Pestell RG
    Front Biosci; 2000 Dec; 5():D938-61. PubMed ID: 11102317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successes and limitations of targeted cancer therapy in breast cancer.
    Curigliano G; Criscitiello C
    Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.
    Johnston SR
    Int J Gynecol Cancer; 2006; 16 Suppl 2():543-8. PubMed ID: 17010069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.
    O'Brien C; Cavet G; Pandita A; Hu X; Haydu L; Mohan S; Toy K; Rivers CS; Modrusan Z; Amler LC; Lackner MR
    Cancer Res; 2008 Jul; 68(13):5380-9. PubMed ID: 18593940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of genomic analysis of breast cancer in drug development.
    Szekely B; Pusztai L
    J Natl Cancer Inst Monogr; 2011; 2011(43):60-2. PubMed ID: 22043042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomics and pharmacogenomics of breast cancer: current knowledge and trends.
    Ayoub N; Lucas C; Kaddoumi A
    Asian Pac J Cancer Prev; 2011; 12(5):1127-40. PubMed ID: 21875255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein tyrosine phosphatases as novel targets in breast cancer therapy.
    Nunes-Xavier CE; Martín-Pérez J; Elson A; Pulido R
    Biochim Biophys Acta; 2013 Dec; 1836(2):211-26. PubMed ID: 23756181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging targeted therapies for metastatic breast cancer.
    Perez EA; Spano JP
    Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.
    Yoshimaru T; Komatsu M; Miyoshi Y; Honda J; Sasa M; Katagiri T
    Cancer Sci; 2015 May; 106(5):550-8. PubMed ID: 25736224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
    Zelnak AB; Wisinski KB
    Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anticancer therapy for breast cancer patients with skin metastases refractory to conventional treatments.
    Varol U; Yildiz I; Alacacioglu A; Uslu R
    Asian Pac J Cancer Prev; 2014; 15(4):1885-7. PubMed ID: 24641425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent developments in treatment stratification for metastatic breast cancer.
    Barton S; Swanton C
    Drugs; 2011 Nov; 71(16):2099-113. PubMed ID: 22035512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.